ATE434034T1 - Rekombinanter vasculärer endothelzellen wachstumsfaktor d (vegf-d) - Google Patents
Rekombinanter vasculärer endothelzellen wachstumsfaktor d (vegf-d)Info
- Publication number
- ATE434034T1 ATE434034T1 AT06121918T AT06121918T ATE434034T1 AT E434034 T1 ATE434034 T1 AT E434034T1 AT 06121918 T AT06121918 T AT 06121918T AT 06121918 T AT06121918 T AT 06121918T AT E434034 T1 ATE434034 T1 AT E434034T1
- Authority
- AT
- Austria
- Prior art keywords
- vegf
- endothelial cell
- growth factor
- cell growth
- vascular endothelial
- Prior art date
Links
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 title 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 title 1
- 210000003556 vascular endothelial cell Anatomy 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 abstract 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2375196P | 1996-08-23 | 1996-08-23 | |
| AUPO1825A AUPO182596A0 (en) | 1996-08-23 | 1996-08-23 | Growth factor |
| AUPO3554A AUPO355496A0 (en) | 1996-11-11 | 1996-11-11 | Growth factor |
| US3109796P | 1996-11-14 | 1996-11-14 | |
| AUPO4954A AUPO495497A0 (en) | 1997-02-05 | 1997-02-05 | Growth factors |
| US3881497P | 1997-02-10 | 1997-02-10 | |
| AUPO7435A AUPO743597A0 (en) | 1997-06-19 | 1997-06-19 | Growth factor |
| US5142697P | 1997-07-01 | 1997-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE434034T1 true ATE434034T1 (de) | 2009-07-15 |
Family
ID=46149776
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06121918T ATE434034T1 (de) | 1996-08-23 | 1997-08-21 | Rekombinanter vasculärer endothelzellen wachstumsfaktor d (vegf-d) |
| AT97938486T ATE306546T1 (de) | 1996-08-23 | 1997-08-21 | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97938486T ATE306546T1 (de) | 1996-08-23 | 1997-08-21 | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
Country Status (10)
| Country | Link |
|---|---|
| US (14) | US6235713B1 (de) |
| EP (4) | EP0956339B1 (de) |
| JP (3) | JP2001517075A (de) |
| AT (2) | ATE434034T1 (de) |
| AU (1) | AU729880C (de) |
| CA (1) | CA2263890C (de) |
| DE (2) | DE69734359T2 (de) |
| DK (3) | DK1749836T3 (de) |
| ES (3) | ES2390107T3 (de) |
| WO (1) | WO1998007832A1 (de) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
| DK0751992T3 (da) | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
| US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
| US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
| US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| PT848755E (pt) | 1995-09-08 | 2003-12-31 | Genentech Inc | Proteina relacionada com o vegf |
| WO1997012972A2 (en) | 1995-09-29 | 1997-04-10 | Universita'degli Studi Di Siena | Regulated genes and uses thereof |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| DE69733204T3 (de) * | 1996-07-15 | 2012-03-08 | Chugai Seiyaku K.K. | Neuartige vegf-ähnliche faktoren |
| EP0956339B1 (de) | 1996-08-23 | 2005-10-12 | Ludwig Institute For Cancer Research | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
| US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| AU765888B2 (en) * | 1997-12-24 | 2003-10-02 | Vegenics Limited | Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas |
| CA2315977A1 (en) * | 1997-12-24 | 1999-07-08 | Ludwig Institute For Cancer Research | Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
| EP1064382B1 (de) | 1998-03-17 | 2008-08-20 | Genentech, Inc. | Zu vegf und bmp1 homologe polypeptide |
| EP0984063A3 (de) * | 1998-08-31 | 2000-08-16 | Eli Lilly And Company | Vegf-verwandtes gen und protein |
| US20030082670A1 (en) * | 1998-09-30 | 2003-05-01 | Ulf Eriksson | Platelet-derived growth factor C, DNA coding therefor, and uses thereof |
| US20040053837A1 (en) * | 1998-09-30 | 2004-03-18 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
| US20030211994A1 (en) * | 1998-09-30 | 2003-11-13 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
| JP4841724B2 (ja) | 1998-10-09 | 2011-12-21 | ベジェニクス ピーティーワイ リミテッド | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
| US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
| EP1568375A1 (de) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Verwendung von VEGF-C oder VEGF-D Genen oder Proteinen zur Vorbeugung der Restenose |
| WO2000024412A2 (en) * | 1998-10-26 | 2000-05-04 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| JP2002534061A (ja) | 1998-11-10 | 2002-10-15 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | 血小板由来増殖因子d、それをコードするdna、及びその利用法 |
| DE69939330D1 (de) * | 1998-12-07 | 2008-09-25 | Zymogenetics Inc | Wachstumsfaktor-homologe zvegf-3 |
| PT1140175E (pt) * | 1998-12-21 | 2006-06-30 | Ludwig Inst Cancer Res | Anticorpos para o vegf-d truncado e suas utilizacoes |
| US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
| IL143832A0 (en) * | 1998-12-22 | 2002-04-21 | Janssen Pharmaceutica Nv | Vascular endothelial growth factor-x |
| US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
| WO2000050620A2 (en) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| WO2000058511A1 (en) | 1999-03-26 | 2000-10-05 | Ludwig Institute For Cancer Research | Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3) |
| US6764820B2 (en) | 1999-03-26 | 2004-07-20 | Ludwig Institute For Cancer Research | Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3) |
| NZ514434A (en) * | 1999-03-26 | 2003-11-28 | Univ California | Modulation of vascular permeability by means of TIE2 receptor activators |
| US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| WO2001012669A1 (en) * | 1999-08-16 | 2001-02-22 | Universita' Degli Studi Di Siena | Vegf-d and angiogenic use thereof |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2001052875A1 (en) | 2000-01-18 | 2001-07-26 | Ludwig Institute For Cancer Research | Vegf-d/vegf-c/vegf peptidomimetic inhibitor |
| US7105168B1 (en) | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
| US6930089B2 (en) | 2000-02-04 | 2005-08-16 | D. Collen Research Foundation Vzw | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke |
| US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
| AU4643501A (en) * | 2000-02-04 | 2001-08-14 | Flanders Interuniversity Institute For Biotechnology (Vib) | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
| PL357099A1 (en) | 2000-02-07 | 2004-07-12 | Abbott Gmbh & Co.Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| AU3988401A (en) | 2000-02-25 | 2001-09-03 | Ludwig Inst Cancer Res | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| US20010038842A1 (en) * | 2000-03-02 | 2001-11-08 | Marc Achen | Methods for treating various cancers expressing vascular endothelial growth factor D, for screening for a neoplastic disease and for maintaining vascularization of tissue |
| DK1259248T3 (da) * | 2000-03-02 | 2005-04-11 | Ludwig Inst Cancer Res | Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D |
| US20020102260A1 (en) * | 2000-03-02 | 2002-08-01 | Marc Achen | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
| AU2006201128B2 (en) * | 2000-03-02 | 2009-05-28 | Vegenics Limited | Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2001082870A2 (en) * | 2000-05-03 | 2001-11-08 | Ludwig Institute For Cancer Research | A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
| KR20020059609A (ko) | 2000-08-04 | 2002-07-13 | 벤슨 로버트 에이치. | 혈관 내피 성장 인자 2 |
| US6793918B2 (en) * | 2000-11-01 | 2004-09-21 | Ludwig Institute For Cancer Research | In vivo stimulation of angiogenic activity |
| WO2002046412A2 (en) | 2000-12-07 | 2002-06-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7611711B2 (en) * | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
| JP4669984B2 (ja) | 2001-01-19 | 2011-04-13 | ベジェニクス リミテッド | 腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法 |
| US20020164624A1 (en) * | 2001-02-12 | 2002-11-07 | Waldemar Debinski | VEGF-D expression in brain cancer |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
| JP2004536579A (ja) | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 血管内皮増殖因子2 |
| WO2002098365A2 (en) * | 2001-06-07 | 2002-12-12 | Skinmedica, Inc. | Conditioned cell culture media and uses thereof |
| AU2002322461B2 (en) * | 2001-07-12 | 2007-12-06 | Vegenics Limited | Lymphatic endothelial cells materials and methods |
| CA2457694A1 (en) * | 2001-08-09 | 2003-02-20 | Cornell Research Foundation, Inc. | Platelet-derived growth factor protection of cardiac myocardium |
| US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
| US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
| CA2462374C (en) | 2001-10-15 | 2011-01-18 | Janssen Pharmaceutica N.V. | Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| WO2003080640A1 (en) * | 2002-03-07 | 2003-10-02 | Ludwig Institute For Cancer Research | Lymphatic and blood endothelial cell genes |
| US7241446B2 (en) * | 2002-04-01 | 2007-07-10 | Trustees Of Dartmouth College | Methods for modulating angiogenesis via VEGF |
| US7510714B2 (en) * | 2002-04-01 | 2009-03-31 | Trustees Of Dartmouth College | Methods for modulating angiogenesis |
| WO2003093419A2 (en) * | 2002-05-03 | 2003-11-13 | Ludwig Institute For Cancer Research | Preventing secondary lymphedema with vegf-d dna |
| AU2003274463B2 (en) | 2002-06-10 | 2009-10-29 | University Of Rochester | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| EP1545588A4 (de) | 2002-07-23 | 2007-12-05 | Ludwig Inst Cancer Res | Verfahren und zusammensetzungen f r die aktivierung oder hemmung von vegf-d und vegf-c |
| US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
| AU2004209668A1 (en) * | 2003-02-04 | 2004-08-19 | Flanders Interuniversity Institute For Biotechnology | VEGF-B and PDGF modulation of stem cells |
| US20050032697A1 (en) * | 2003-06-12 | 2005-02-10 | Kari Alitalo | Heparin binding VEGFR-3 ligands |
| WO2005011722A2 (en) * | 2003-06-12 | 2005-02-10 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d in reconstructive surgery |
| WO2005026362A2 (en) * | 2003-09-08 | 2005-03-24 | Ludwig Institute For Cancer Reserach | Lymphatic and blood endothelial cell genes |
| US7284505B1 (en) | 2003-11-03 | 2007-10-23 | Paxton Stephen E | Skijor system |
| US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
| EP1699819A2 (de) * | 2003-12-29 | 2006-09-13 | Centelion | Behandlung von koronarer oder peripherer ischämie |
| US20050142161A1 (en) * | 2003-12-30 | 2005-06-30 | Freeman Lynetta J. | Collagen matrix for soft tissue augmentation |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| US20060024302A1 (en) | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
| WO2005093098A1 (en) * | 2004-03-12 | 2005-10-06 | Ludwig Institute For Cancer Research | Differential drug sensitivity |
| US7595149B1 (en) | 2004-11-08 | 2009-09-29 | University Of Kentucky Research Foundation | Methods for cancer detection |
| CA2599004C (en) | 2005-02-28 | 2015-05-26 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
| ES2363758T3 (es) | 2005-08-15 | 2011-08-16 | Vegenics Pty Ltd | Vegf y pdgf modificados con propiedades angiogénicas mejoradas. |
| TW200732347A (en) * | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| JP2009523807A (ja) | 2006-01-18 | 2009-06-25 | ザ ジェネラル ホスピタル コーポレイション | リンパ機能を高める方法 |
| ES2429225T3 (es) | 2006-05-17 | 2013-11-13 | The Ludwig Institute For Cancer Research | Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico |
| EP2125895B1 (de) | 2007-02-02 | 2015-04-08 | Vegenics Pty Ltd | Vegf-rezeptorantagonisten zur behandlung von allommunität bei organtransplantationen und atherosklerose |
| US20080267924A1 (en) * | 2007-02-07 | 2008-10-30 | Vegenics Limited | Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery |
| US7811776B2 (en) | 2007-12-05 | 2010-10-12 | University Of Cincinnati | Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease |
| NZ586544A (en) | 2007-12-26 | 2012-07-27 | Vaccinex Inc | Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods |
| WO2009143584A1 (en) * | 2008-05-30 | 2009-12-03 | Vegenics Limited | Treatment of pulmonary edema |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
| US8255807B2 (en) * | 2008-12-23 | 2012-08-28 | Ganz | Item customization and website customization |
| JP2012522491A (ja) * | 2009-04-03 | 2012-09-27 | ベジニクス ピーティーワイ リミテッド | 抗vegf−d抗体 |
| WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
| US9011861B2 (en) * | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| WO2011154308A1 (en) | 2010-06-08 | 2011-12-15 | Proyecto De Biomedicina Cima, S.L. | New compositions and cell therapy methods for the treatment of cirrhosis |
| WO2012088563A1 (en) * | 2010-11-24 | 2012-07-05 | Vegenics Pty Limited | Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof |
| WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
| US9415090B2 (en) * | 2011-06-01 | 2016-08-16 | Universität Heidelberg | VEGF-D/VEGFR2/3-mediated regulation of dendrites |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| JP6429774B2 (ja) | 2012-07-30 | 2018-11-28 | トロホジェン・インコーポレーテッド | 糖タンパク質ホルモン長期作用性スーパーアゴニスト |
| US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
| ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
| WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| MY170528A (en) | 2013-02-18 | 2019-08-09 | Vegenics Pty Ltd | Vegfr-3 ligand binding molecules and uses thereof |
| DK2962113T3 (da) | 2013-02-28 | 2019-07-01 | Biocare Medical Llc | Systemer og fremgangsmåder med anti-p40-antistoffer |
| US9816997B2 (en) | 2013-10-03 | 2017-11-14 | Biocare Medical, Llc | Anti-SOX10 antibody systems and methods |
| KR20160101906A (ko) | 2013-11-05 | 2016-08-26 | 트로포젠 인코포레이티드 | 당단백질 호르몬의 장시간-작용하는 초작용제 |
| WO2020202214A2 (en) * | 2019-04-04 | 2020-10-08 | Sree Chitra Tirunal Institute For Medical Sciences And Technology | Vascular endothelial growth factor (vegf) for better wound healing through enhanced angiogenesis |
| WO2022191252A1 (ja) * | 2021-03-10 | 2022-09-15 | 住友ファーマ株式会社 | システインノットタンパク質の製造方法 |
| WO2024259161A2 (en) * | 2023-06-14 | 2024-12-19 | Yale University | Methods and compositions for treating respiratory disorders |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968778A (en) | 1989-01-12 | 1999-10-19 | Jurgen Hoppe | PDGF-AB, preparation process and pharmaceuticals containing them |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US6207454B1 (en) * | 1989-10-16 | 2001-03-27 | Amgen Inc. | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide |
| US5476839A (en) * | 1990-07-10 | 1995-12-19 | Incyte Pharmaceuticals, Inc. | Basophil granule proteins |
| JP3024311B2 (ja) | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
| JPH05271294A (ja) | 1992-01-24 | 1993-10-19 | Japan Found Cancer Res | ヒトプロヒビチンおよびそれをコードするdna |
| EP0656905B1 (de) | 1992-07-27 | 1997-09-03 | Pfizer Inc. | Calcium-kanal blockierende polypeptide aus agelenopsis aperta |
| US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
| DK0751992T3 (da) * | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
| DE4423098A1 (de) | 1994-07-01 | 1996-01-04 | Hoechst Ag | Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US6221839B1 (en) * | 1994-11-14 | 2001-04-24 | Helsinki University Licensing Ltd. Oy | FIt4 ligand and methods of use |
| US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
| JPH08185216A (ja) | 1994-12-28 | 1996-07-16 | Meidensha Corp | 工具姿勢パラメータ設定方法及びロボット制御装置 |
| US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| WO1996027007A1 (en) | 1995-03-02 | 1996-09-06 | Amrad Operations Pty. Ltd. | A novel growth factor and a genetic sequence encoding same |
| CA2224002A1 (en) | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 3 |
| PT848755E (pt) * | 1995-09-08 | 2003-12-31 | Genentech Inc | Proteina relacionada com o vegf |
| WO1997012972A2 (en) * | 1995-09-29 | 1997-04-10 | Universita'degli Studi Di Siena | Regulated genes and uses thereof |
| JP3843488B2 (ja) | 1996-06-06 | 2006-11-08 | アイシン・エィ・ダブリュ株式会社 | 自動変速機の制御装置 |
| DE69733204T3 (de) | 1996-07-15 | 2012-03-08 | Chugai Seiyaku K.K. | Neuartige vegf-ähnliche faktoren |
| EP0956339B1 (de) | 1996-08-23 | 2005-10-12 | Ludwig Institute For Cancer Research | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
| AU5439998A (en) * | 1996-12-06 | 1998-06-29 | Zymogenetics Inc. | Vascular endothelial growth factor |
| US20020165174A1 (en) * | 1997-01-31 | 2002-11-07 | Gill Parkash S. | Methods and compositions for antisense VEGF oligonucleotides |
| CA2315977A1 (en) | 1997-12-24 | 1999-07-08 | Ludwig Institute For Cancer Research | Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
| DE19817835C2 (de) | 1998-04-22 | 2000-05-18 | Billhofer Maschf Gmbh | Sichtkaschiervorrichtung |
| DE19823359C1 (de) | 1998-05-15 | 1999-10-07 | Francotyp Postalia Gmbh | Vorrichtung zum Bedrucken von Postgut |
| PT1140175E (pt) | 1998-12-21 | 2006-06-30 | Ludwig Inst Cancer Res | Anticorpos para o vegf-d truncado e suas utilizacoes |
| WO2001012669A1 (en) * | 1999-08-16 | 2001-02-22 | Universita' Degli Studi Di Siena | Vegf-d and angiogenic use thereof |
| WO2005011722A2 (en) | 2003-06-12 | 2005-02-10 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d in reconstructive surgery |
| US20070212390A1 (en) | 2005-09-22 | 2007-09-13 | Ludwig Institute For Cancer Research | Protease-resistant forms of VEGF-D, method of making and method of use |
| FR2987282B1 (fr) | 2012-02-24 | 2017-12-29 | Fonds De L'espci Georges Charpak | Microcanal avec dispositif d'ouverture et/ou fermeture et/ou pompage |
| US9405291B2 (en) | 2012-07-31 | 2016-08-02 | Fisher-Rosemount Systems, Inc. | Systems and methods to monitor an asset in an operating process unit |
| US9516755B2 (en) | 2012-12-28 | 2016-12-06 | Intel Corporation | Multi-channel memory module |
| US9426605B2 (en) | 2013-10-10 | 2016-08-23 | Yahoo! Inc. | Cross device information exchange using gestures and locations |
-
1997
- 1997-08-21 EP EP97938486A patent/EP0956339B1/de not_active Revoked
- 1997-08-21 DE DE69734359T patent/DE69734359T2/de not_active Expired - Lifetime
- 1997-08-21 AT AT06121918T patent/ATE434034T1/de not_active IP Right Cessation
- 1997-08-21 EP EP09162873A patent/EP2107109B1/de not_active Expired - Lifetime
- 1997-08-21 US US08/915,795 patent/US6235713B1/en not_active Expired - Fee Related
- 1997-08-21 WO PCT/US1997/014696 patent/WO1998007832A1/en not_active Ceased
- 1997-08-21 ES ES09162873T patent/ES2390107T3/es not_active Expired - Lifetime
- 1997-08-21 JP JP51095398A patent/JP2001517075A/ja active Pending
- 1997-08-21 DK DK06121918T patent/DK1749836T3/da active
- 1997-08-21 ES ES97938486T patent/ES2251740T3/es not_active Expired - Lifetime
- 1997-08-21 AT AT97938486T patent/ATE306546T1/de not_active IP Right Cessation
- 1997-08-21 DE DE69739469T patent/DE69739469D1/de not_active Expired - Lifetime
- 1997-08-21 EP EP06121918A patent/EP1749836B1/de not_active Expired - Lifetime
- 1997-08-21 DK DK09162873.5T patent/DK2107109T3/da active
- 1997-08-21 ES ES06121918T patent/ES2327440T3/es not_active Expired - Lifetime
- 1997-08-21 CA CA2263890A patent/CA2263890C/en not_active Expired - Fee Related
- 1997-08-21 AU AU40796/97A patent/AU729880C/en not_active Ceased
- 1997-08-21 DK DK97938486T patent/DK0956339T3/da active
- 1997-08-21 EP EP02018842A patent/EP1283268A3/de not_active Withdrawn
-
1999
- 1999-04-22 US US09/296,275 patent/US6689580B1/en not_active Expired - Fee Related
-
2002
- 2002-06-05 US US10/161,694 patent/US7410639B2/en not_active Expired - Fee Related
- 2002-10-22 US US10/274,953 patent/US7122654B2/en not_active Expired - Fee Related
-
2003
- 2003-11-12 US US10/705,476 patent/US20040175730A1/en not_active Abandoned
-
2005
- 2005-12-16 US US11/304,585 patent/US20060177428A1/en not_active Abandoned
-
2007
- 2007-01-24 JP JP2007013569A patent/JP2007167072A/ja active Pending
- 2007-03-28 US US11/692,753 patent/US20080145366A1/en not_active Abandoned
- 2007-06-29 US US11/772,089 patent/US7662932B2/en not_active Expired - Fee Related
- 2007-08-23 US US11/843,867 patent/US7871798B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,537 patent/US7785803B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,120 patent/US7928061B2/en not_active Expired - Fee Related
-
2009
- 2009-07-10 JP JP2009164162A patent/JP2009291198A/ja active Pending
-
2011
- 2011-03-16 US US13/049,308 patent/US8227410B2/en not_active Expired - Fee Related
-
2012
- 2012-05-17 US US13/474,273 patent/US8445234B2/en not_active Expired - Fee Related
-
2013
- 2013-04-19 US US13/866,266 patent/US8759286B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE306546T1 (de) | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) | |
| NO973933L (no) | Vaskulær endotelvekstfaktor B | |
| DE69941791D1 (de) | Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen | |
| ATE110108T1 (de) | Genetische modifizierung von endothelialen zellen. | |
| PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
| DE69839340D1 (de) | Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN | |
| ATE90966T1 (de) | Expression von protein-c. | |
| ZA943464B (en) | Vascular endothelial growth factor 2 | |
| ATE114169T1 (de) | Morphogenetisches knochenprotein. | |
| DK288183D0 (da) | Fremgangsmade til fremstilling af et oligonucleotidt terapeutisk middel | |
| ES2141761T3 (es) | Secuencias de dna codificantes de nuevos factores de crecimiento/diferenciacion. | |
| ATE293168T1 (de) | Thrombin mutanten | |
| DE3580283D1 (de) | Biologisch wirksame substanz mit hormonellen eigenschaften, verfahren zu ihrer herstellung und verwendung von histonen fuer medizinische zwecke. | |
| IL70776A (en) | Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides | |
| NO892033L (no) | Fibronectinbindende protein. | |
| DE3751269D1 (de) | Expression des biologisch aktiven Faktors XIII. | |
| SE8902507L (sv) | Neutrofil-aktiverande faktor | |
| WO2001040257A3 (en) | Modified il-12 subunits and nucleic acids encoding them | |
| WO2001053324A3 (en) | Novel haptotactic peptides | |
| WO1990003394A3 (fr) | Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines | |
| DK1633440T3 (da) | Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler | |
| WO2002059618A3 (en) | Growth factor polypeptides and nucleic acids encoding same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |